Lyra Therapeutics, Inc.
LYRA
$10.68
$0.403.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.19M | 1.53M | 1.47M | 1.82M | 1.68M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.19M | 1.53M | 1.47M | 1.82M | 1.68M |
| Cost of Revenue | 30.40M | 43.77M | 49.67M | 56.14M | 53.67M |
| Gross Profit | -29.22M | -42.23M | -48.20M | -54.32M | -51.99M |
| SG&A Expenses | 15.95M | 18.50M | 19.25M | 20.32M | 19.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.35M | 62.27M | 68.92M | 76.45M | 73.42M |
| Operating Income | -45.17M | -60.73M | -67.44M | -74.63M | -71.74M |
| Income Before Tax | -79.50M | -93.40M | -97.56M | -101.33M | -68.82M |
| Income Tax Expenses | 29.00K | 39.00K | 50.00K | 59.00K | 59.00K |
| Earnings from Continuing Operations | -79.53 | -93.44 | -97.61 | -101.39 | -68.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.53M | -93.44M | -97.61M | -101.39M | -68.88M |
| EBIT | -45.17M | -60.73M | -67.44M | -74.63M | -71.74M |
| EBITDA | -44.70M | -60.26M | -67.04M | -74.20M | -71.32M |
| EPS Basic | -60.71 | -71.75 | -75.69 | -83.67 | -64.78 |
| Normalized Basic EPS | -20.51 | -27.82 | -31.06 | -37.38 | -39.32 |
| EPS Diluted | -60.71 | -71.75 | -75.69 | -83.67 | -64.78 |
| Normalized Diluted EPS | -20.51 | -27.82 | -31.06 | -37.38 | -39.32 |
| Average Basic Shares Outstanding | 5.24M | 5.21M | 5.13M | 4.74M | 4.30M |
| Average Diluted Shares Outstanding | 5.24M | 5.21M | 5.13M | 4.74M | 4.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |